Literature DB >> 9194760

Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study.

B Lamarche1, S Moorjani, B Cantin, G R Dagenais, P J Lupien, J P Després.   

Abstract

Individuals with elevated plasma concentrations of HDL cholesterol are at lower risk for ischemic heart disease (IHD). Whether the cardioprotective effects of HDL can be attributed to one or both HDL subfractions (HDL2 and HDL3) remains, however, controversial. The relationship of HDL subfractions to the incidence of IHD was investigated in a sample of 1169 French-Canadian men younger than 60 years and living in the Quebec City suburbs. Between 1980 to 1981 and 1990, 83 of the 944 men with complete follow-up in 1990 (80.8%) had a first IHD. Men who developed IHD had lower HDL, HDL2, and HDL3 cholesterol concentrations at baseline than men who remained free from IHD. Adjusted relative risk (RR) of IHD was calculated among quartiles of HDL cholesterol and HDL subfractions with the use of Cox survival models. Men in the fourth quartile of HDL2 (RR = 0.21; 95% confidence interval [CI], 0.08 to 0.56) and HDL3 cholesterol distributions (RR = 0.37; 95% CI, 0.15 to 0.94) were at lower risk for IHD than men in the first quartile. Despite the fact that the respective contributions of HDL2 and HDL3 to IHD risk were of the same magnitude in a multivariate model that included both subfractions, the contribution of the HDL2 subfraction was statistically significant (standardized RR = 0.84; 95% CI, 0.74 to 0.95), whereas it did not reach significance for HDL3 (standardized RR = 0.87; 95% CI, 0.69 to 1.11). Neither the linear combination of HDL2 and HDL3 nor their ratio provided further information on the risk of IHD compared with HDL cholesterol alone or with the ratio of total to HDL cholesterol. From a statistical standpoint, the present data suggest that the HDL2 subfraction may be more closely related to the development of IHD than the HDL3 subfraction. However, the qualitative difference in the relative predictive value of each subfraction was trivial, since it only corresponded to a modest quantitative difference. Thus, the possibility that a significant proportion of the cardioprotective effect of elevated HDL cholesterol levels may be mediated by the HDL3 subfraction still cannot be excluded. Finally, from a clinical point of view and within the limits of resolution provided by these data, the measurement of HDL subfractions does not appear to provide any additional information on the risk of IHD than HDL cholesterol alone or the ratio of total to HDL cholesterol.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9194760     DOI: 10.1161/01.atv.17.6.1098

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  37 in total

1.  Does simultaneous determination of LDL and HDL particle size improve prediction of coronary artery disease risk?

Authors:  Aleksandra Zeljkovic; Vesna Spasojevic-Kalimanovska; Jelena Vekic; Zorana Jelic-Ivanovic; Aleksandra Topic; Natasa Bogavac-Stanojevic; Slavica Spasic; Ana Vujovic; Dimitra Kalimanovska-Ostric
Journal:  Clin Exp Med       Date:  2008-07-11       Impact factor: 3.984

2.  Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies.

Authors:  Parag H Joshi; Peter P Toth; Seth T Lirette; Michael E Griswold; Joseph M Massaro; Seth S Martin; Michael J Blaha; Krishnaji R Kulkarni; Arif A Khokhar; Adolfo Correa; Ralph B D'Agustino; Steven R Jones
Journal:  Eur J Prev Cardiol       Date:  2014-07-25       Impact factor: 7.804

3.  HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative.

Authors:  Seth S Martin; Arif A Khokhar; Heidi T May; Krishnaji R Kulkarni; Michael J Blaha; Parag H Joshi; Peter P Toth; Joseph B Muhlestein; Jeffrey L Anderson; Stacey Knight; Yan Li; John A Spertus; Steven R Jones
Journal:  Eur Heart J       Date:  2014-06-30       Impact factor: 29.983

Review 4.  The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype.

Authors:  John D Brunzell; Alberto Zambon; Samir S Deeb
Journal:  Biochim Biophys Acta       Date:  2011-09-25

5.  HDL in CKD: how good is the "good cholesterol?".

Authors:  Ian H de Boer; John D Brunzell
Journal:  J Am Soc Nephrol       Date:  2014-03-07       Impact factor: 10.121

6.  Subfractions of High-Density Lipoprotein-Cholesterol and Carotid Intima-Media Thickness: The Northern Manhattan Study.

Authors:  Eduard Tiozzo; Hannah Gardener; Barry I Hudson; Chuanhui Dong; David Della-Morte; Milita Crisby; Ronald B Goldberg; Mitchell S V Elkind; Ying Kuen Cheung; Clinton B Wright; Ralph L Sacco; Moise Desvarieux; Tatjana Rundek
Journal:  Stroke       Date:  2016-05-10       Impact factor: 7.914

7.  Aldosterone production in human adrenocortical cells is stimulated by high-density lipoprotein 2 (HDL2) through increased expression of aldosterone synthase (CYP11B2).

Authors:  Yewei Xing; Anthony Cohen; George Rothblat; Sandhya Sankaranarayanan; Ginny Weibel; Lori Royer; Omar L Francone; William E Rainey
Journal:  Endocrinology       Date:  2011-01-14       Impact factor: 4.736

8.  Bone marrow-derived HL mitigates bone marrow-derived CETP-mediated decreases in HDL in mice globally deficient in HL and the LDLr.

Authors:  Neil J Hime; Audrey S Black; David J Bonnet; Linda K Curtiss
Journal:  J Lipid Res       Date:  2014-05-12       Impact factor: 5.922

9.  Association of LIPC -250G>A polymorphism and several environmental factors with serum lipid levels in the Guangxi Bai Ku Yao and Han populations.

Authors:  Li Meng; Yin Ruixing; Li Yiyang; Long Xingjiang; Li Kela; Liu Wanying; Zhang Lin; Lin Weixiong; Yang Dezhai; Pan Shangling
Journal:  Lipids Health Dis       Date:  2010-03-11       Impact factor: 3.876

Review 10.  Role of fibric acid derivatives in the management of risk factors for coronary heart disease.

Authors:  Jean-Pierre Després; Isabelle Lemieux; Sander J Robins
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.